TransMedics outlines $737M-$757M 2026 revenue outlook while targeting 30,000 transplants by 2032 (NASDAQ:TMDX)
· seekingalpha.com
TransMedics (TMDX) Q2 2026 earnings call highlights: record $190M revenue, raised 2026 guidance, margin outlook, PAD dilution and catalysts—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...